Compare McKesson Corporation (MCK) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Schwab US Dividend Equity ETF — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: McKesson Corporation and Schwab US Dividend Equity ETF are close in size by market cap, and McKesson Corporation pays a 0.4% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| MCK | SCHD | |
|---|---|---|
Market Cap | $108.46B | $110.56B |
Volume | 712,607 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $35.21 |
52-Week Low | $725.17 | $26.44 |
Typical Hold Time | 74 Days | 62 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
SCHD trades at $33.15, up 1.53% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 by nearly 10 percentage points in 2026, with recent dividend growth attracting income-focused investors. Technical indicators show neutral oscillators but strong trend momentum with ADX readings above 60.
SCHD offers dividend growth potential with lower fees than competitors, though its defensive tilt may lag in growth markets. Key risks include interest rate sensitivity and methodology constraints that excluded high-performing stocks like Broadcom. The current pullback from August highs presents a potential entry point for long-term dividend investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
